Navigation Links
Trudeau Institute announces a discovery in the fight against sepsis
Date:7/11/2011

Saranac Lake, N.Y. New research from the Trudeau Institute may help to explain why anticoagulant therapies have largely failed to extend the lives of patients with sepsis. The study was led by Deyan Luo, a postdoctoral fellow in Stephen Smiley's laboratory. It shows that fibrin, a key product of the blood clotting process, is critical for host defense against Yersinia enterocolitica, a gram-negative bacterium that causes sepsis in humans and experimental mice. The new data will be published in the August 15 issue of The Journal of Immunology and is available now online ahead of print.

"After inoculating a variety of genetically engineered mice with this bacterium, the lab observed that mice lacking fibrin showed dramatically decreased survival and harbored greatly increased numbers of bacteria in their blood and tissues," said Dr. Smiley. "These findings add to a growing body of evidence that fibrin helps to protect our bodies during infection."

Infectious disease remains a leading cause of death worldwide. Many of these deaths actually result, in large part, from our bodies' own excessive responses to certain types of infections. Whether the infectious agents first gain access to our bodies via a wound, intravenous line, or catheter, and whether they first establish infections in our skin, lung or intestine, all too often they evade our natural immune defense mechanisms and then spread, causing a generalized infection throughout much of the body.

Unless effective antibiotics are administered promptly, these generalized infections can lead to sepsis, a syndrome in which the immune system unleashes so much infection-fighting inflammation that it causes more damage than good, leading to organ failure, shock and death. With the ever-growing presence of multiple drug resistant bacteria like MRSA, the incidence of sepsis is increasing, even in state-of-the-art hospitals. Typically doctors simply tell family members that these deaths are caused by infection, but in many cases the true cause of death is sepsis.

One reason sepsis is difficult to treat is that the excessive inflammatory response prompts changes in another powerful system of our bodies, the blood clotting system. Blood is supposed to clot in response to trauma, as a means to prevent bleeding. However, the excessive inflammation that accompanies sepsis causes blood to clot within our blood vessels, even in the absence of trauma, thereby blocking blood flow and starving tissues of life-giving oxygen. It seems logical to treat sepsis patients with drugs that stop blood clotting (i.e. anticoagulants). However, anticoagulant therapies have largely failed to extend the lives of patients with sepsis. The Trudeau study provides a dramatic demonstration of the importance of the blood clotting process during sepsis, thus helping to explain why anticoagulants typically fail to help sepsis patients.

Additionally, the Trudeau study identified a number of molecular players key to regulating the levels of fibrin produced by the protective blood clotting pathway. The Smiley lab hypothesizes that drugs for sepsis will need to maintain these protective pathways, while preventing the excessive, oxygen-depriving, blood clotting that causes organ failure. Importantly, they identified at least one drug target that may allow them to selectively prevent the damaging blood clots while maintaining the protective fibrin. Specifically, they showed that the "extrinsic" blood clotting pathway is critical for protective clotting during sepsis whereas the "intrinsic" pathway appears to be dispensable. Ongoing studies aim to assess whether anticoagulant drugs that selectively block this intrinsic pathway will help to prevent deaths from infections that cause sepsis.


'/>"/>

Contact: Karen Sharma
518-891-3080
Trudeau Institute
Source:Eurekalert

Related biology technology :

1. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
2. Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community
3. Colorado Institute for Drug, Device and Diagnostic Development Awards Funding to Fort Collins-based VetDC
4. Karlsruhe Institute of Technology: Self-assembling electronic nano-components
5. Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery
6. David H. Murdock Research Institute Assumes Control of the Immune Tolerance Institute and Establishes a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development
7. Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma
8. Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies
9. Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris Novel Cancer Drug, ADI-PEG 20
10. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
11. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building ... challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ranked ... its increasing popularity is due to its new team building format, a way for teams ...
(Date:3/23/2017)... 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ... for solid tumor cancers, today announced that yesterday ... announced last Friday, March 17, 2017. ... securities totaling 28,843,692 shares, comprised of 18,843,692 common ... of Class C Warrants pre-funded at the closing ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... Branford, CT (PRWEB) , ... March 23, 2017 ... ... Counsel, LLC, was recently selected by the Connecticut Technology Council (CTC) as a ... honored at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner ...
Breaking Biology Technology:
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
(Date:3/7/2017)... CITY , March 7, 2017   HireVue ... help top global companies identify the best talent, faster, ... as Chief Sales Officer (CSO) and Diana Kucer ... appointments round out a seasoned executive team poised to drive ... beyond, building on a year of record bookings in ...
(Date:3/2/2017)... LONDON , March 2, 2017 Who ... infringement lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... ON THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using ... smartphones. The fingerprint sensor vendor Idex forecasts an increase ... in mobile devices and of the fingerprint sensor market ...
Breaking Biology News(10 mins):